Decrease of rapid-eye-movement sleep in the light by intraventricular application of a VIP-antagonist in the rat.
Vasoactive intestinal polypeptide (VIP) has been shown to increase the amount of time spent in rapid-eye-movement (REM) sleep both in cats and in rats. In the present study we examined the effect of a newly available competitive VIP-antagonist ([4Cl-D-Phe6-Leu17]-VIP) on sleep-wake patterns in male rats during both the light and the dark phase of 24 h. Continuous intracerebroventricular application of this VIP-antagonist reduced by 44% the amount of time spent in REM sleep during the light period. It is concluded that VIP may play a role in the generation and maintenance of REM sleep.
Mirmiran
M
M
Netherlands Institute for Brain Research, Amsterdam.
Kruisbrink
J
J
Bos
N P
NP
Van der Werf
D
D
Boer
G J
GJ
D000818:Animals; D002552:Cerebral Ventricles / Q000187:drug effects / Q000502:physiology*; D007276:Injections, Intraventricular; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values; D012895:Sleep, REM / Q000187:drug effects*; D014660:Vasoactive Intestinal Peptide / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000494:pharmacology
C048507:vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-; D014660:Vasoactive Intestinal Peptide